INDAPTUS THERAPEUTICS INC (INDP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.16-4.24%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INDP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
INDP — private placement
Dated 2026-10-20
Other Events. On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placement, the Company will issue an aggregate of 20,338,974 Shares to the Purchasers. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behal…
Why it matters: Second-quarter costs fell, but the company still reported a net loss. Faster cash use could raise the need for more funding.
Worry ifThe November 11 report shows quarterly operating costs above about $1.8 million, the Q2 level. Cash use is above the recent pace.
Less concerning ifThe November 11 report shows operating costs at or below about $1.8 million. Cash use is no faster than the prior half-year pace.
Why it matters: The collaboration is a new research path as Decoy20 work has been cut back. Clear data could support its next research steps.
Supportive ifA company update shares study results or data. These link sleep or brain measures with immune status.
Worry ifA company update says the work ended, or found no useful link between the measures studied.
Why it matters: The June report showed $11.6 million in cash and short-term investments. New figures will show how that balance changed after new financing.
Watch forThe November 11 report shows more than $11.6 million in cash and short-term investments. Operating cash use is no higher than the prior half-year pace.
Also watch forThe report shows less than $11.6 million in cash and short-term investments, or operating cash use above the prior half-year pace.
Why it matters: The company has no active clinical programs. A completed deal could set its next business path.
Supportive ifA company filing names a completed investment, purchase, or business deal. It gives the deal terms.
Worry ifA later company update says no deal was completed. The strategic review is still open.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$574 on $10,000 · ±5.7% | How much price usually moves either way. |
| Bad day | $1,464 loss on $10,000 · 14.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,029 loss on $10,000 · 80.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.